# Gilead Sciences Moat

Status: published. Policy: company-analysis-1.

Gilead has a narrow moat supported by pharmaceutical intellectual property, approved product differentiation and demonstrated HIV commercial leadership. Record sales and Biktarvy's reported prescription leadership support a current advantage; Yeztugo's approval establishes differentiation, but its long-term commercial contribution remains potential. Substantial discounts constrain realized pricing power. Missing product-level patent timelines, competitor comparisons and patient persistence data prevent a wide-moat conclusion.

## intangible_assets

Patents, licensed intellectual property and approved differentiated medicines support a current advantage. The supplied disclosures report record 2025 sales driven by Biktarvy, described as the most-prescribed HIV treatment, and FDA approval of Yeztugo as the first twice-yearly HIV prevention. Recognized licensing revenues provide additional evidence that intellectual property is monetized.

Durability: Protection is finite and product-specific. Management expects no major loss of exclusivity for the coming decade, but the passages provide no product-level expiration schedule or independent validation of that expectation. Yeztugo's approval is demonstrated; durable future growth is management's forecast.

Risks: Generic challenges, patent invalidation, competing therapies and reimbursement restrictions can erode exclusivity, demand and net pricing. Significant existing discounts already constrain price realization. Manufacturing complexity establishes operational requirements, but does not by itself demonstrate superior economics.

Invalidation: The thesis would weaken materially if earlier generic entry or patent invalidation affected major products, Biktarvy lost prescription leadership alongside sustained base-business sales declines, or payer concessions persistently reduced net revenue despite stable demand. Failure of new products to replace revenue lost after exclusivity would further invalidate durability.

Competitors: Not established
- [https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm](https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/gild-20251231.htm) · 2026-02-24
- [https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm](https://www.sec.gov/Archives/edgar/data/882095/000088209526000031/gild-20260630.htm) · 2026-08-06
- [https://www.sec.gov/Archives/edgar/data/882095/000130817926000106/gild014721-def14a.htm](https://www.sec.gov/Archives/edgar/data/882095/000130817926000106/gild014721-def14a.htm) · 2026-03-20

[JSON](https://beanvest.com/stock/gild/moat.json)